Eutropoflavin
4'-DMA-7 · 8-DHF · 4'-dimethylamino-7 · 8-dihydroxyflavone · 2-[4-(dimethylamino)phenyl]-7 · 8-dihydroxy-4H-chromen-4-one
Last updated
At a glance
Overview
Why Eutropoflavin Earned Its Reputation#
Eutropoflavin — the 4'-dimethylamino analog of 7,8-DHF, also written as 4'-DMA-7,8-DHF — is one of the few small molecules in the nootropic space with a credible mechanistic story for directly engaging the BDNF → TrkB axis from an oral dose. The community reaches for it for the same reasons the original Emory papers flagged it: stronger TrkB agonism than the parent 7,8-DHF, longer receptor engagement, and documented downstream effects on hippocampal neurogenesis and mood in rodent models.
"The 4′-dimethylamino group on the B ring substantially increased the TrkB agonistic activity and extended the duration of receptor activation in cultured neurons and in the brain after oral administration." — Liu et al., J. Med. Chem. (2010)
Practically, users run it for three overlapping use cases: cognitive performance (sharper focus, mild mood lift, better plasticity during heavy learning or training blocks), subclinical low-mood / anhedonia support (where the chronic-dosing antidepressant-like signal is strongest), and long-horizon neuroprotection as part of a broader longevity stack. A secondary PDXP-inhibition arm — shared with the parent catechol — raises brain PLP (active vitamin B6) and likely contributes to the subjective cognitive effect beyond TrkB alone. It is non-hormonal, requires no PCT, and sits comfortably alongside peptides, racetams, lion's mane, creatine, and omega-3.
It is not a stimulant and it is not a single-dose compound — the plasticity effects surface over 1–2 weeks of consistent BID dosing, and a meaningful non-responder rate is part of the class. The sections below cover the eutropoflavin dosage ladder, BID timing logic around the short plasma half-life, stack design for focus, mood, and neuroprotection, documented side effects (appetite suppression is the one to plan around), sourcing notes, and the most common protocol mistakes reported in community reviews.
How Eutropoflavin works
TrkB Receptor Agonism — The Primary BDNF-Mimetic Arm#
Eutropoflavin is a small-molecule agonist of tropomyosin receptor kinase B (TrkB), the receptor that BDNF itself binds to drive neuronal survival, synaptic plasticity, and long-term potentiation. Binding the extracellular domain of TrkB drives receptor dimerization and autophosphorylation of intracellular tyrosines, which then recruits Shc/FRS2 adapters and fires three downstream cascades in parallel: PI3K → AKT (pro-survival, anti-apoptotic), Ras → MAPK/ERK (plasticity and CREB-driven transcription), and PLCγ1 → PKC/Ca²⁺ (acute synaptic modulation).
The 4'-dimethylamino substitution on the B-ring is what distinguishes eutropoflavin from its parent 7,8-DHF — it pushes both potency and duration of receptor engagement higher:
"the 4′-dimethylamino group on the B ring substantially increased the TrkB agonistic activity and extended the duration of receptor activation in cultured neurons and in the brain after oral administration." — Liu X. et al., Journal of Medicinal Chemistry, 2010
The practical consequence for the reader: this is a BDNF-axis signaling enhancer, which is the same pathway that exercise, caloric sufficiency, and deep sleep recruit. Stacking it on top of those inputs is additive; using it to paper over sleep deprivation is not.
Antidepressant and Anhedonia-Lifting Effects#
Chronic TrkB activation in the hippocampus drives adult neurogenesis in the dentate gyrus and remodels prefrontal and limbic synaptic architecture — the same endpoints that SSRIs, ketamine, and exercise converge on, but reached from a different direction. In rodent depression models, eutropoflavin outperformed the parent compound on both potency and efficacy:
"Orally administered 4′-dimethylamino-7,8-dihydroxyflavone displayed robust antidepressant activity in mice, with superior potency and efficacy compared to the parent compound." — Liu X. et al., Journal of Medicinal Chemistry, 2012
This is why single-dose trials mislead users into thinking the compound "does nothing." The mood and anhedonia lift tracks neurogenesis, which needs 2–4 weeks of chronic dosing to surface. The acute subjective response (mild clarity, light mood lift within ~60 minutes of administration) is a secondary phenomenon; the main effect is slow-build.
Vitamin B6 / PDXP Inhibition — The Secondary Arm#
The 7,8-catechol on the A-ring — retained in eutropoflavin — is a direct, reversible inhibitor of pyridoxal 5'-phosphatase (PDXP), the enzyme that dephosphorylates active vitamin B6 (PLP) in the brain. Inhibiting PDXP raises brain PLP, which in turn drives synthesis of GABA, dopamine, serotonin, and glycine — all PLP-dependent pathways.
"7,8-dihydroxyflavone directly and reversibly inhibits pyridoxal phosphatase (PDXP), raising PLP levels in the brain in a PDXP-dependent manner." — Brenner M. et al., eLife, 2024
This is a relatively recent mechanistic finding and it reframes the class. The subjective neurotransmitter-modulation flavor that users report — sharper focus, steadier mood, better verbal fluency — is plausibly as much a PLP story as a TrkB story. For stack design, it also means concurrent high-dose B6 supplementation can produce larger PLP shifts than expected; not clinically concerning on its own, but worth noting in complex nootropic stacks.
Blood–Brain Barrier Penetration and Central Exposure#
Unlike BDNF itself (a 27 kDa protein that does not cross the BBB and is useless orally), eutropoflavin is a small, lipophilic flavone (LogP ~2.47, MW 297) that penetrates the CNS after oral administration. The parent scaffold was specifically selected on this basis:
"7,8-DHF readily penetrates the blood-brain barrier and activates TrkB in the brain to promote neurogenesis and synaptic plasticity." — Jang S-W. et al., PNAS, 2010
Central activity after a peripheral oral dose is what makes the class interesting at all — it's the key reason eutropoflavin is pursued rather than recombinant BDNF.
Pharmacokinetic Constraints and Why BID Dosing Matters#
The weakness of the scaffold is pharmacokinetic, not pharmacodynamic. Oral bioavailability is low (single-digit to ~10%), the catechol is rapidly conjugated by phase-II enzymes and methylated by COMT, and plasma half-life sits at roughly 1–2 hours:
"Eutropoflavin derivatives demonstrated rapid plasma clearance and low absolute oral bioavailability, with prodrug strategies required to optimize brain exposure for therapeutic effect." — Chen C. et al., PNAS, 2018
Three practical consequences:
| PK property | Consequence for protocol design |
|---|---|
| Short plasma t½ (~1–2 h) | BID dosing (AM + early PM) maintains TrkB engagement across the day |
| Low oral F (~5–10%) | Sublingual is sometimes trialed; mg doses are higher than the in-vitro potency suggests |
| Catechol oxidation | Capsules stored cool, dry, and light-protected; degraded material underperforms |
| Chronic-dosing-dependent endpoints | 2–4 week minimum trial; single-dose tests are uninformative |
The compound rewards a patient, consistent protocol. It does not reward a stimulant-style "hit it hard on the day you need it" approach — the neurogenesis and synaptic-remodeling payoff is cumulative, and the subjective target after 2–3 weeks is "quietly sharper, steadier mood, slightly suppressed appetite," not a dramatic acute effect.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 10–10 mg | Twice daily | Documented entry-level range |
| Mid | 10–20 mg | Twice daily | Most commonly studied range |
| High | 20–40 mg | Twice daily | Short plasma half-life favors BID dosing — AM plus early-afternoon is the standard split. Evening administration may disrupt sleep onset in sensitive subjects; afternoon cut-off is the common practice. |
Cycle length & outcomes
Documented cycle
4–8 weeks
Plateau after
8 wks
Eutropoflavin doesn't follow the anabolic-cycle playbook — there's no HPG-axis suppression to recover from, no loading phase, no taper. What matters is chronic consistent exposure long enough for the TrkB-driven plasticity effects to surface, because the compound is a slow-burn BDNF-axis agent, not an acute stimulant.
"the 4′-dimethylamino group on the B ring substantially increased the TrkB agonistic activity and extended the duration of receptor activation in cultured neurons and in the brain after oral administration." — Liu et al., J. Med. Chem. 2010
Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose | Split |
|---|---|---|---|
| Tolerance assessment / first exposure | 1–2 weeks | 10 mg | AM only |
| Cognitive performance (focus, memory) | 4–6 weeks | 10–20 mg | AM + early PM |
| Mood / anhedonia protocols | 6–8 weeks | 20 mg | 10 mg BID |
| Neuroprotection / longevity maintenance | 8 weeks on / 2 off, repeating | 10 mg | AM only |
| High-responder optimization | 4–8 weeks | 30–40 mg | 15–20 mg BID |
| Recovery adjunct around heavy training blocks | 4–6 weeks | 20 mg | AM + early PM |
Onset Timing — Set Expectations Correctly#
The most common reason the community reports "it doesn't work" is a single-dose trial. The pharmacology splits into two windows:
- Acute (30–90 minutes): Mild mood lift, subtle focus sharpening, occasional appetite suppression. Peak plasma at ~1–2 hours. This is real but unremarkable — it is not a stimulant.
- Chronic (2–4 weeks): The plasticity substrate. Neurogenesis, synaptic remodeling, and the durable mood effects demonstrated in rodents require sustained TrkB engagement.
"Orally administered 4′-dimethylamino-7,8-dihydroxyflavone displayed robust antidepressant activity in mice, with superior potency and efficacy compared to the parent compound." — Liu et al., J. Med. Chem. 2012
Protocols shorter than 4 weeks are diagnostic at best — enough to assess tolerance and acute response, not enough to see the mechanism's main output. The 4–8 week window is where the literature's neurogenesis and antidepressant endpoints map onto subjective effects in practice.
Dosing Frequency — Why BID Is the Default#
Plasma half-life sits at ~1–2 hours, with bioavailability around 8% after first-pass metabolism of the catechol. A single morning dose produces a sharp central window that fades by afternoon.
"Eutropoflavin derivatives demonstrated rapid plasma clearance and low absolute oral bioavailability, with prodrug strategies required to optimize brain exposure for therapeutic effect." — Chen et al., PNAS 2018
The practical consequence: 10 mg AM + 10 mg early afternoon is the standard community split. The second dose lands before the afternoon cut-off (roughly 2–3 PM) — later dosing can intrude on sleep onset in sensitive subjects, since even mild TrkB-driven arousal stacks poorly with melatonin timing. Sublingual administration is sometimes trialed to sidestep first-pass metabolism; reports are mixed and the difference is subtle rather than transformative.
Loading, Tapering, and Tolerance#
- No loading phase. Front-loading doesn't accelerate the plasticity response — it just increases early-cycle appetite suppression and headache complaints.
- No taper required. There is no receptor downregulation to manage, no rebound, no withdrawal. The compound can be stopped cleanly.
- Tolerance is modest but real. Subjective novelty fades after 6–8 weeks of continuous dosing. Two patterns work well:
- 8-on / 2-off: preserves the subjective edge while maintaining the neurogenesis substrate.
- 5-on / 2-off (weekday dosing): popular for cognitive-performance use cases where weekday sharpness is the goal.
Continuous open-ended dosing is also defensible for neuroprotection-focused protocols, where the goal is chronic low-grade BDNF-axis support rather than phasic cognitive output.
Bloodwork Cadence#
No specific monitoring is required. The compound has no HPG-axis activity, no hepatotoxicity signal in preclinical work, no lipid or hematocrit impact, and no interaction with standard bodybuilding bloodwork panels. Subjects running eutropoflavin alongside AAS or SARM protocols do not need to add anything to the standard on-cycle panel.
For chronic use at the 20 mg BID ceiling beyond 6 months, an annual CBC/CMP is reasonable baseline hygiene — not because a specific risk is documented, but because any chronic small-molecule intervention benefits from a low-cost monitoring floor.
The one mechanism-specific note: concurrent high-dose vitamin B6 supplementation stacks with the PDXP-inhibition arm of the mechanism.
"7,8-dihydroxyflavone directly and reversibly inhibits pyridoxal phosphatase (PDXP), raising PLP levels in the brain in a PDXP-dependent manner." — Brenner et al., eLife 2024
This is not clinically problematic at nutritional B6 doses, but megadose B6 (100+ mg/day) alongside chronic eutropoflavin is worth flagging in complex stacks — exaggerated PLP shifts are mechanistically predictable even if not clinically observed.
Practical Cycle Structure#
A typical first cycle for the cognitive/mood use case:
- Week 1: 10 mg AM only. Assess acute response, appetite, sleep.
- Week 2: 10 mg AM + 10 mg early PM. Hold at 20 mg/day.
- Weeks 3–6: Maintain 20 mg/day. Plasticity effects surface in this window.
- Weeks 7–8: Optional extension, or taper off cleanly.
- Weeks 9–10: Washout. Re-baseline subjective state before deciding on a second block.
Stack additions should be introduced after week 2, not before — attribution is impossible if three novel compounds start on day one. Lion's mane, creatine, and high-EPA omega-3s are the most common companions and all pull in the same BDNF-axis direction without confounding the readout.
Non-response is a real class feature, not a vendor or protocol failure. If 6 weeks at 20 mg/day produces nothing subjective, the compound is unlikely to be a good fit at any dose — pushing to 40 mg/day rarely rescues a non-responder and reliably worsens the appetite suppression.
Risks & mistakes
Common (most users)#
- Appetite suppression — the most consistently reported effect. Useful in a cut, a liability in a lean bulk. Mitigation: front-load protein and calories at breakfast before the AM dose, or shift dosing to post-meal rather than fasted.
- Mild acute stimulation or "wired" feeling after the first few doses, particularly at 20mg single-dose. Usually resolves within the first week as TrkB signaling normalizes. Mitigation: start at 10mg once-daily for 3–5 days before splitting to BID.
- Sleep disruption from late dosing — the short plasma half-life doesn't prevent a residual CNS effect that pushes sleep onset in sensitive subjects. Mitigation: hard afternoon cut-off (second dose no later than ~2 PM).
- Vivid or unusually salient dreams — consistent with TrkB's role in synaptic consolidation. Not a problem, but worth flagging. No mitigation needed.
- Transient headache or mild frontal pressure in the first week. Usually self-resolves; hydration and dropping to 10mg once-daily for a few days clears it.
- "Nothing" — a meaningful share of the user base reports no subjective effect even after a proper 2-week chronic trial. This is a genuine pharmacogenomic feature of the class, not a sourcing issue. Mitigation: give it a full 2–3 weeks at 10mg BID before concluding non-response; if still flat, the compound is not a fit.
Uncommon (dose-dependent or individual)#
- Flattened affect / mild anhedonia at the 20mg BID ceiling. The BDNF/TrkB axis is not linear — pushing past the plateau tends to invert the mood benefit rather than amplify it. Mitigation: drop to 10mg BID; effect reverses within 3–5 days.
- Jaw tension, mild restlessness in the first few hours post-dose at higher exposures. Back off 25–50% and reassess.
- Exaggerated PLP shifts when stacked with high-dose vitamin B6 (>25mg pyridoxine or P5P daily). The catechol directly inhibits PDXP, so concurrent B6 supplementation produces larger brain PLP swings than expected (Brenner et al., eLife 2024). Not clinically dangerous, but worth knowing in complex stacks — keep B6 at RDA-range if running eutropoflavin chronically.
- GI upset from poorly-stored or oxidized material. The 7,8-catechol is oxidation-prone; degraded capsules can taste metallic and irritate. Mitigation: source from a vendor with COA, keep sealed, dry, light-protected.
- Tolerance / diminishing returns after 6–8 weeks of continuous dosing. Mitigation: build in a 1–2 week washout between 4–8 week blocks, or run 5-on / 2-off.
Rare but serious#
- No serious adverse events have been reported in the publicly available literature or community write-ups at community doses. The compound has not entered human clinical trials, so there is no controlled safety database — the absence of reports is partly an absence of structured monitoring.
- Theoretical tumorigenic concern via chronic TrkB pathway activation. BDNF/TrkB signaling is implicated in the biology of neuroblastoma and a handful of epithelial cancers. No human case reports link eutropoflavin or 7,8-DHF to tumor promotion, but the mechanistic plausibility means the conservative position is to avoid chronic dosing with active or recent malignancy in TrkB-expressing tissue.
- Persistent mood destabilization — if affect flattens, anxiety spikes, or sleep degrades and does not reverse within a week of dose reduction, discontinue.
Hard contraindications#
- Active or recent malignancy in TrkB-expressing tissue — neuroblastoma, certain gliomas, and some prostate and pancreatic cancers. Do not run.
- Pregnancy and lactation — no safety data in either model or clinical setting. Avoid.
- History of TrkB-driven tumor biology in first-degree relatives where the user has an established genetic predisposition — defer to oncology guidance, do not experiment.
Gender, PCT, and stack considerations#
Eutropoflavin has no androgenic, estrogenic, progestogenic, or HPG-axis activity. Dosing is identical across the subject pool; no PCT is required, and no hormonal bloodwork disruption is expected. Women and men respond on the same protocol.
For stack hygiene: the compound plays well with lion's mane, creatine, omega-3 EPA/DHA, magnesium, and standard cognitive-optimization ancillaries. It does not require — and generally does not benefit from — stacking with stimulants; the acute effect profile is already mildly activating. Anyone running heavy orals or on an aggressive AAS protocol will find eutropoflavin neutral to the hormonal axis, which makes it one of the cleaner cognitive ancillaries to layer into a cycle without adding bloodwork complications.
FAQ — Eutropoflavin
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy 4’-DMA-7,8-DHF ( Eutropoflavin ) 10mg / 60 capsule - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Eutropoflavin
Research & citations
5 studies cited on this page.
Conclusion
Eutropoflavin stands out as a potent, research-grade TrkB/BDNF-pathway agonist — the most advanced analog of the 7,8-dihydroxyflavone class, with enhanced receptor activity and durability over the parent compound.
Key takeaways:
- Standard protocol: 10 mg twice daily (AM + early afternoon), oral capsule
- Short plasma half-life favors BID administration for sustained effect
- Cycle length: typically 4–8 weeks, with washout blocks to prevent tolerance
- Primary endpoint: cognitive plasticity, mood elevation, and neuroprotection
- Most effective stacked with cholinergics, omega-3s, lion's mane, or racetams
- Appetite suppression is common; a feature or bug depending on research goals
- Contraindicated in active/recent malignancy involving TrkB+ tissues and during pregnancy/lactation
For any research application targeting enhanced cognitive performance, mood stabilization, or neuroprotective signaling, eutropoflavin is one of the top options within the nootropic and neurotrophic research toolbox.